BANU K ARUN to Mutation
This is a "connection" page, showing publications BANU K ARUN has written about Mutation.
Connection Strength
2.466
-
BRCA mutations in women with inflammatory breast cancer. Cancer. 2018 02 01; 124(3):466-474.
Score: 0.144
-
The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. Int J Oncol. 2015 Jul; 47(1):262-8.
Score: 0.122
-
Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers. Breast J. 2015 May-Jun; 21(3):260-7.
Score: 0.121
-
Genetic risk assessment for breast and gynecological malignancies. Curr Opin Obstet Gynecol. 2015 Feb; 27(1):1-5.
Score: 0.120
-
Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer. 2012 Jan 15; 118(2):321-5.
Score: 0.095
-
Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer. 2012 Mar 15; 118(6):1515-22.
Score: 0.094
-
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011 Nov; 130(1):145-53.
Score: 0.094
-
Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010 Sep 20; 28(27):4214-20.
Score: 0.088
-
Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer. 2009 Feb 15; 115(4):725-30.
Score: 0.079
-
High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res (Phila). 2009 Feb; 2(2):122-7.
Score: 0.079
-
BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol. 2007 Oct 10; 25(29):4635-41.
Score: 0.072
-
Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations. Cancer. 2024 May 01; 130(9):1600-1608.
Score: 0.055
-
Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers. Breast Cancer Res Treat. 2022 Nov; 196(1):143-152.
Score: 0.050
-
Clinical outcomes and Oncotype DX Breast Recurrence Score? in early-stage BRCA-associated hormone receptor-positive breast cancer. Cancer Med. 2022 03; 11(6):1474-1483.
Score: 0.049
-
Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center. Cancer. 2022 Jan 01; 128(1):94-102.
Score: 0.047
-
PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations. Cancer J. 2021 Jan-Feb 01; 27(1):67-75.
Score: 0.045
-
Clinical implications of breast cancer tumor genomic testing. Breast J. 2020 08; 26(8):1565-1571.
Score: 0.044
-
Multigene panel testing results in patients with multiple breast cancer primaries. Breast J. 2020 07; 26(7):1337-1342.
Score: 0.042
-
EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer. Nanomedicine (Lond). 2019 09; 14(17):2315-2338.
Score: 0.041
-
The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2019 11 15; 105(4):698-712.
Score: 0.041
-
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 07; 121(2):180-192.
Score: 0.040
-
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. J Natl Cancer Inst. 2019 04 01; 111(4):350-364.
Score: 0.040
-
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat. 2018 05; 39(5):593-620.
Score: 0.037
-
Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue. Cancer. 2018 02 15; 124(4):866.
Score: 0.036
-
BRCA mutation genetic testing implications in the United States. Breast. 2017 Feb; 31:224-232.
Score: 0.034
-
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat. 2017 01; 161(1):117-134.
Score: 0.034
-
Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers. Oncologist. 2016 07; 21(7):869-74.
Score: 0.033
-
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2016 06; 157(2):319-327.
Score: 0.033
-
Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat. 2016 Jan; 155(1):165-73.
Score: 0.032
-
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res. 2015 Apr 25; 17:61.
Score: 0.030
-
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 07; 313(13):1347-61.
Score: 0.030
-
Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. PLoS One. 2015; 10(4):e0120020.
Score: 0.030
-
Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less. Breast. 2014 Dec; 23(6):770-4.
Score: 0.029
-
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015 Jan 15; 121(2):269-75.
Score: 0.029
-
Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol. 2014 Oct; 21(11):3466-72.
Score: 0.028
-
Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing. Hum Pathol. 2012 Nov; 43(11):1932-9.
Score: 0.025
-
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011 Oct 01; 29(28):3739-46.
Score: 0.024
-
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011 Mar 01; 17(5):1082-9.
Score: 0.023
-
Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res Treat. 2010 Nov; 124(2):441-51.
Score: 0.021
-
Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer. 2009 Apr 15; 115(8):1598-604.
Score: 0.020
-
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008 Sep 10; 26(26):4282-8.
Score: 0.019
-
Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer. 2006 Dec 15; 107(12):2745-51.
Score: 0.017
-
Assessing BRCA carrier probabilities in extended families. J Clin Oncol. 2006 Jan 20; 24(3):354-60.
Score: 0.016
-
Hematologic malignancies in Li-Fraumeni syndrome: A case report. Am J Med Genet A. 2024 07; 194(7):e63573.
Score: 0.014
-
Protein-folding chaperones predict structure-function relationships and cancer risk in BRCA1 mutation carriers. Cell Rep. 2024 Feb 27; 43(2):113803.
Score: 0.014
-
Helping Patients Understand and Cope with BRCA Mutations. Curr Oncol Rep. 2022 06; 24(6):733-740.
Score: 0.012
-
Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):426-436.
Score: 0.012
-
Molecular Spectra and Frequency Patterns of Somatic Mutations in Arab Women with Breast Cancer. Oncologist. 2021 11; 26(11):e2086-e2089.
Score: 0.012
-
Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes. Cancer. 2021 10 01; 127(19):3605-3613.
Score: 0.012
-
Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover). Clin Cancer Res. 2021 09 15; 27(18):4983-4993.
Score: 0.012
-
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genet Med. 2021 09; 23(9):1726-1737.
Score: 0.012
-
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021 02 17; 12(1):1078.
Score: 0.011
-
Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing. Ann Surg Oncol. 2020 Nov; 27(12):4613-4621.
Score: 0.011
-
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med. 2020 10; 22(10):1653-1666.
Score: 0.011
-
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet. 2020 06; 52(6):572-581.
Score: 0.011
-
Imaging Features of Triple Negative Breast Cancer and the Effect of BRCA Mutations. Curr Probl Diagn Radiol. 2021 May-Jun; 50(3):303-307.
Score: 0.011
-
Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. Breast J. 2019 07; 25(4):575-577.
Score: 0.010
-
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer. 2008 Nov 15; 113(10):2627-37.
Score: 0.010
-
Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer. J Glob Oncol. 2018 08; 4:1-9.
Score: 0.010
-
Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer. J Natl Compr Canc Netw. 2017 06; 15(6):797-803.
Score: 0.009
-
Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes. Oncologist. 2017 06; 22(6):655-666.
Score: 0.009
-
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May; 49(5):680-691.
Score: 0.009
-
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res. 2016 06 21; 18(1):64.
Score: 0.008
-
Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nat Commun. 2016 04 27; 7:11375.
Score: 0.008
-
A two-stage approach to genetic risk assessment in primary care. Breast Cancer Res Treat. 2016 Jan; 155(2):375-83.
Score: 0.008
-
BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing. Oncologist. 2015 Jun; 20(6):593-7.
Score: 0.008
-
Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):308-16.
Score: 0.007
-
Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis. Oncologist. 2014 Aug; 19(8):797-804.
Score: 0.007
-
Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer. 2014 May 15; 120(10):1557-64.
Score: 0.007
-
Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Res Treat. 2013 Jun; 139(2):571-9.
Score: 0.007
-
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013; 9(3):e1003212.
Score: 0.007
-
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Breast J. 2009 Jan-Feb; 15(1):4-16.
Score: 0.005
-
Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol. 2006 Sep; 108(3 Pt 1):515-20.
Score: 0.004